Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation

References

• Martin PJ, Counts GW, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28:1011–1016.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230–2239.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087–1092.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715–4726.
   PubMed Web of Science ®Google Scholar
• Wang HT, Chang YJ, Xu LP, et al. EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation. Bone Marrow Transplant. 2014;49:927–933.
   PubMed Web of Science ®Google Scholar
• Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121:2854–2863.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919.
   PubMed Web of Science ®Google Scholar
• Raimondi R, Tosetto A, Oneto R, et al. Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood. 2012;120:1327–1333.
   PubMed Web of Science ®Google Scholar
• Mo XD, Xu LP, Liu DH, et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol. 2013;88:497–502.
   PubMed Web of Science ®Google Scholar
• Barba P, Martino R, Pérez-Simón JA, et al. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:66–72.
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Liu KY, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15:257–265.
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291–297.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–3219.
   PubMed Web of Science ®Google Scholar
• Zhao XS, Liu YR, Zhu HH, et al. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012;91:183–192.
   PubMed Web of Science ®Google Scholar
• Zhao XS, Jin S, Zhu HH, et al. Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012;47:499–507.
   PubMed Web of Science ®Google Scholar
• Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119:3256–3262.
   PubMed Web of Science ®Google Scholar
• Huang XJ, Wang Y, Liu DH, et al. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant. 2009;44:309–316.
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Liu KY, et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92:414–417.
   PubMed Web of Science ®Google Scholar
• Posada D, Buckley TR. Model selection and model averaging in phylogenetics: advantages of Akaike information criterion and Bayesian approaches over likelihood ratio tests. Syst Biol. 2004;53:793–808.
   PubMed Web of Science ®Google Scholar
• Liu J, Xu LP, Liu DH, et al. [A new multi-factor risk score system for predicting the outcome after allogenic hematopoietic stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22:117–124.
   PubMedGoogle Scholar
• Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:362–387.
   Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109–2123.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.
   PubMed Web of Science ®Google Scholar
• Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–3073.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Huang XJ. Haploidentical bone marrow transplantation without T-cell depletion. Semin Oncol. 2012;39:653–663.
   PubMed Web of Science ®Google Scholar
• ElSawy M, Storer BE, Sorror ML. “To combine or not to combine”: optimizing risk assessment before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1455–1456.
   PubMed Web of Science ®Google Scholar
• Hemmati PG, Terwey TH, le Coutre P, et al. A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. Eur J Haematol. 2011;86:305–316.
   PubMed Web of Science ®Google Scholar
• Terwey TH, Hemmati PG, Martus P, et al. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica. 2010;95:810–818.
   PubMed Web of Science ®Google Scholar
• Michelis FV, Messner HA, Uhm J, et al. Modified EBMT pretransplant risk score can identify favorable-risk patients undergoing allogeneic hematopoietic cell transplantation for AML, not identified by the HCT-CI score. Clin Lymphoma Myeloma Leuk. 2015;15:e73–e81.
   PubMedGoogle Scholar